JP2021513844A5 - - Google Patents
Info
- Publication number
- JP2021513844A5 JP2021513844A5 JP2020543351A JP2020543351A JP2021513844A5 JP 2021513844 A5 JP2021513844 A5 JP 2021513844A5 JP 2020543351 A JP2020543351 A JP 2020543351A JP 2020543351 A JP2020543351 A JP 2020543351A JP 2021513844 A5 JP2021513844 A5 JP 2021513844A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- occupied
- conjugated
- item
- seq
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023067166A JP2023089195A (ja) | 2018-02-15 | 2023-04-17 | グリピカン３抗体およびそのコンジュゲート |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862631353P | 2018-02-15 | 2018-02-15 | |
| US62/631,353 | 2018-02-15 | ||
| PCT/US2019/018182 WO2019161174A1 (en) | 2018-02-15 | 2019-02-15 | Glypican 3 antibodies and conjugates thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023067166A Division JP2023089195A (ja) | 2018-02-15 | 2023-04-17 | グリピカン３抗体およびそのコンジュゲート |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021513844A JP2021513844A (ja) | 2021-06-03 |
| JP2021513844A5 true JP2021513844A5 (https=) | 2022-02-22 |
| JPWO2019161174A5 JPWO2019161174A5 (https=) | 2022-02-22 |
| JP7402807B2 JP7402807B2 (ja) | 2023-12-21 |
Family
ID=67620075
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543351A Active JP7402807B2 (ja) | 2018-02-15 | 2019-02-15 | グリピカン３抗体およびそのコンジュゲート |
| JP2023067166A Pending JP2023089195A (ja) | 2018-02-15 | 2023-04-17 | グリピカン３抗体およびそのコンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023067166A Pending JP2023089195A (ja) | 2018-02-15 | 2023-04-17 | グリピカン３抗体およびそのコンジュゲート |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11819553B2 (https=) |
| EP (1) | EP3752534A4 (https=) |
| JP (2) | JP7402807B2 (https=) |
| KR (1) | KR20200121317A (https=) |
| CN (1) | CN111712520A (https=) |
| AR (1) | AR114112A1 (https=) |
| AU (1) | AU2019220700A1 (https=) |
| CA (1) | CA3090251A1 (https=) |
| IL (1) | IL276514B2 (https=) |
| MX (1) | MX2020008030A (https=) |
| SG (1) | SG11202007073SA (https=) |
| TW (1) | TWI851552B (https=) |
| WO (1) | WO2019161174A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019001302A (es) | 2016-08-09 | 2019-06-12 | Seattle Genetics Inc | Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas. |
| AR114112A1 (es) | 2018-02-15 | 2020-07-22 | Seattle Genetics Inc | Anticuerpos de glipicano 3 y conjugados de los mismos |
| CA3170023A1 (en) * | 2020-02-27 | 2021-09-02 | Nanjing Legend Biotech Co., Ltd. | Antibodies and chimeric antigen receptors targeting glypican-3 (gpc3) and methods of use thereof |
| WO2021207701A1 (en) | 2020-04-10 | 2021-10-14 | Seagen Inc. | Charge variant linkers |
| EP4146702A4 (en) * | 2020-05-07 | 2024-07-10 | Phanes Therapeutics, Inc. | Anti-tumor associated antigen antibodies and uses thereof |
| AU2022238571A1 (en) | 2021-03-18 | 2023-09-14 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| CN112921005B (zh) * | 2021-04-14 | 2023-07-07 | 中国农业科学院兰州兽医研究所 | 一株杂交瘤细胞株及其产生的犬细小病毒vp2蛋白单克隆抗体和应用 |
| CA3221398A1 (en) | 2021-05-28 | 2022-12-01 | Seagen Inc. | Anthracycline antibody conjugates |
| IL310866A (en) * | 2021-08-19 | 2024-04-01 | Adicet Therapeutics Inc | Methods for the detection of membrane-bound glypican-3 |
| WO2023045151A1 (en) * | 2021-09-24 | 2023-03-30 | Zhejiang Shimai Pharmaceutical Co., Ltd. | Antibodies against gpc3 and uses thereof |
| IL315508A (en) | 2022-03-17 | 2024-11-01 | Seagen Inc | Camptothecin conjugates |
| WO2023207475A1 (zh) * | 2022-04-24 | 2023-11-02 | 昱言科技(北京)有限公司 | 靶向gpc3的单克隆抗体和包含此抗体的抗体药物缀合物 |
| CN119894536A (zh) * | 2022-09-22 | 2025-04-25 | 乐普生物科技股份有限公司 | Gpc3抗体药物偶联物及其应用 |
| CN119968398A (zh) * | 2022-11-28 | 2025-05-09 | 四川科伦博泰生物医药股份有限公司 | 靶向gpc3的抗体及其用途 |
| WO2024129756A1 (en) | 2022-12-13 | 2024-06-20 | Seagen Inc. | Site-specific engineered cysteine antibody drug conjugates |
| CN119424671A (zh) * | 2023-08-01 | 2025-02-14 | 上海新理念生物医药科技有限公司 | 含糖基吡啶型连接子的抗体药物偶联物 |
| WO2025090774A1 (en) | 2023-10-24 | 2025-05-01 | Seagen Inc. | Chemotherapeutic compounds and methods of use |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7361336B1 (en) | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
| CA2451493C (en) | 2001-06-22 | 2016-08-23 | Chugai Seiyaku Kabushiki Kaisha | Cell growth inhibitors containing anti-glypican 3 antibody |
| WO2004022597A1 (ja) | 2002-09-04 | 2004-03-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体 |
| CN1842540B (zh) * | 2004-07-09 | 2012-07-04 | 中外制药株式会社 | 抗-磷脂酰肌醇蛋白聚糖3抗体 |
| BR112012012912A2 (pt) | 2009-11-30 | 2016-10-25 | Biotest Ag | anticorpo ou fragmento do mesmo, ácido nucleico, vetor, célula hospedeira, método para a produção de um anticorpo ou um fragmento do mesmo, composição farmacêutica, método para tratar ou prevenir uma condição médica em um indivíduo, uso de um anticorpo ou fragmento do mesmo e métodos in vitro para neutralizar il-10 em uma amostra e para detectar a presença de il-10 em uma amostra. |
| CN113933504A (zh) * | 2014-05-08 | 2022-01-14 | 中外制药株式会社 | 对gpc3靶向治疗剂疗法有效的患者施用的gpc3靶向治疗剂 |
| WO2015179658A2 (en) | 2014-05-22 | 2015-11-26 | Genentech, Inc. | Anti-gpc3 antibodies and immunoconjugates |
| EP2963057A1 (en) | 2014-07-02 | 2016-01-06 | Calypso Biotech SA | Antibodies to IL-15 |
| SI3900742T1 (sl) * | 2014-09-11 | 2024-10-30 | Seagen Inc. | Ciljana dostava zdravilnih snovi, ki vsebujejo terciarne amine |
| WO2017181109A1 (en) * | 2016-04-15 | 2017-10-19 | Michael Molloy | Anti-human vista antibodies and use thereof |
| US20170326249A1 (en) * | 2016-05-10 | 2017-11-16 | Bristol-Myers Squibb Company | Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses |
| AR114112A1 (es) | 2018-02-15 | 2020-07-22 | Seattle Genetics Inc | Anticuerpos de glipicano 3 y conjugados de los mismos |
-
2019
- 2019-02-14 AR ARP190100366A patent/AR114112A1/es not_active Application Discontinuation
- 2019-02-15 CA CA3090251A patent/CA3090251A1/en active Pending
- 2019-02-15 TW TW108105041A patent/TWI851552B/zh active
- 2019-02-15 MX MX2020008030A patent/MX2020008030A/es unknown
- 2019-02-15 US US16/970,095 patent/US11819553B2/en active Active
- 2019-02-15 CN CN201980012811.4A patent/CN111712520A/zh active Pending
- 2019-02-15 WO PCT/US2019/018182 patent/WO2019161174A1/en not_active Ceased
- 2019-02-15 SG SG11202007073SA patent/SG11202007073SA/en unknown
- 2019-02-15 IL IL276514A patent/IL276514B2/en unknown
- 2019-02-15 JP JP2020543351A patent/JP7402807B2/ja active Active
- 2019-02-15 EP EP19755133.6A patent/EP3752534A4/en not_active Withdrawn
- 2019-02-15 AU AU2019220700A patent/AU2019220700A1/en not_active Abandoned
- 2019-02-15 KR KR1020207025196A patent/KR20200121317A/ko not_active Ceased
-
2023
- 2023-04-17 JP JP2023067166A patent/JP2023089195A/ja active Pending
- 2023-10-13 US US18/486,335 patent/US20240173427A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021513844A5 (https=) | ||
| JP6366111B2 (ja) | 有効性の改善および毒性の減少のための、抗体およびｓｎ−３８からなるイムノコンジュゲートの投薬 | |
| AU2025201862A1 (en) | Combination of antibody-drug conjugate and immune checkpoint inhibitor | |
| JPWO2019161174A5 (https=) | ||
| JP2021511058A5 (https=) | ||
| JP2016531915A5 (https=) | ||
| JP7724866B2 (ja) | 抗体薬物複合体およびその用途 | |
| JP2012522512A5 (https=) | ||
| JP2011507932A5 (https=) | ||
| JP2021513844A (ja) | グリピカン３抗体およびそのコンジュゲート | |
| KR20180023915A (ko) | Cl2a 링커를 갖는 항체-sn-38 면역접합체 | |
| JP2017522861A5 (https=) | ||
| JP2012522513A5 (https=) | ||
| TW202310879A (zh) | 抗體－藥物結合物之用途 | |
| JP2008526234A5 (https=) | ||
| WO2021067820A1 (en) | Formulation of antibody-drug conjugate | |
| JPWO2019147831A5 (https=) | ||
| JP2021501776A5 (https=) | ||
| KR20180100412A (ko) | 면역강화제에 의해 증진되는 초항원 매개된 암 면역요법 | |
| CN108778332B (zh) | Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途 | |
| JP2020507339A (ja) | 抗ｇ−ｃｓｆ抗体及びその使用 | |
| CN118076387A (zh) | 靶向表达cdh17的肿瘤的多特异性抗体及其制备和使用方法 | |
| US20250339548A1 (en) | Method for treating cancer by using antibody-drug conjugate and use | |
| TWI763956B (zh) | 治療癌症的抗前胃泌激素抗體與免疫療法之組合療法 | |
| JP2015529656A5 (https=) |